Hsin-Chieh Yeh1,2,3,4, Nisa M Maruthur1,2,3, Nae-Yuh Wang1,2,3,5, Gerald J Jerome1,6, Arlene T Dalcin1,3, Eva Tseng1,3, Karen White1, Edgar R Miller1,2,3, Stephen P Juraschek1,7, Noel T Mueller2,3, Jeanne Charleston2,3, Nowella Durkin1, Ahmed Hassoon2,4, Dina G Lansey4, Norma F Kanarek4,8, Michael A Carducci4, Lawrence J Appel1,2,3,9. 1. Department of Medicine, Johns Hopkins University, Baltimore, MD, USA. 2. Department of Epidemiology, Johns Hopkins University, Baltimore, MD, USA. 3. Welch Center for Prevention, Epidemiology, and Clinical Research, Baltimore, MD, USA. 4. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. 5. Department of Biostatistics, Johns Hopkins University, Baltimore, MD, USA. 6. Department of Kinesiology, Towson University, Towson, MD, USA. 7. Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA. 8. Department of Environmental Health and Engineering, Johns Hopkins University, Baltimore, MD, USA. 9. Department of International Health (Human Nutrition), Johns Hopkins University, Baltimore, MD, USA.
Abstract
CONTEXT: Higher levels of insulin-like growth factor-1 (IGF-1) are associated with increased risk of cancers and higher mortality. Therapies that reduce IGF-1 have considerable appeal as means to prevent recurrence. DESIGN: Randomized, 3-parallel-arm controlled clinical trial. INTERVENTIONS AND OUTCOMES: Cancer survivors with overweight or obesity were randomized to (1) self-directed weight loss (comparison), (2) coach-directed weight loss, or (3) metformin treatment. Main outcomes were changes in IGF-1 and IGF-1:IGFBP3 molar ratio at 6 months. The trial duration was 12 months. RESULTS: Of the 121 randomized participants, 79% were women, 46% were African Americans, and the mean age was 60 years. At baseline, the average body mass index was 35 kg/m2; mean IGF-1 was 72.9 (SD, 21.7) ng/mL; and mean IGF1:IGFBP3 molar ratio was 0.17 (SD, 0.05). At 6 months, weight changes were -1.0% (P = 0.07), -4.2% (P < 0.0001), and -2.8% (P < 0.0001) in self-directed, coach-directed, and metformin groups, respectively. Compared with the self-directed group, participants in metformin had significant decreases on IGF-1 (mean difference in change: -5.50 ng/mL, P = 0.02) and IGF1:IGFBP3 molar ratio (mean difference in change: -0.0119, P = 0.011) at 3 months. The significant decrease of IGF-1 remained in participants with obesity at 6 months (mean difference in change: -7.2 ng/mL; 95% CI: -13.3 to -1.1), but not in participants with overweight (P for interaction = 0.045). There were no significant differences in changes between the coach-directed and self-directed groups. There were no differences in outcomes at 12 months. CONCLUSIONS: In cancer survivors with obesity, metformin may have a short-term effect on IGF-1 reduction that wanes over time.
CONTEXT: Higher levels of insulin-like growth factor-1 (IGF-1) are associated with increased risk of cancers and higher mortality. Therapies that reduce IGF-1 have considerable appeal as means to prevent recurrence. DESIGN: Randomized, 3-parallel-arm controlled clinical trial. INTERVENTIONS AND OUTCOMES: Cancer survivors with overweight or obesity were randomized to (1) self-directed weight loss (comparison), (2) coach-directed weight loss, or (3) metformin treatment. Main outcomes were changes in IGF-1 and IGF-1:IGFBP3 molar ratio at 6 months. The trial duration was 12 months. RESULTS: Of the 121 randomized participants, 79% were women, 46% were African Americans, and the mean age was 60 years. At baseline, the average body mass index was 35 kg/m2; mean IGF-1 was 72.9 (SD, 21.7) ng/mL; and mean IGF1:IGFBP3 molar ratio was 0.17 (SD, 0.05). At 6 months, weight changes were -1.0% (P = 0.07), -4.2% (P < 0.0001), and -2.8% (P < 0.0001) in self-directed, coach-directed, and metformin groups, respectively. Compared with the self-directed group, participants in metformin had significant decreases on IGF-1 (mean difference in change: -5.50 ng/mL, P = 0.02) and IGF1:IGFBP3 molar ratio (mean difference in change: -0.0119, P = 0.011) at 3 months. The significant decrease of IGF-1 remained in participants with obesity at 6 months (mean difference in change: -7.2 ng/mL; 95% CI: -13.3 to -1.1), but not in participants with overweight (P for interaction = 0.045). There were no significant differences in changes between the coach-directed and self-directed groups. There were no differences in outcomes at 12 months. CONCLUSIONS: In cancer survivors with obesity, metformin may have a short-term effect on IGF-1 reduction that wanes over time.
Authors: E S Schernhammer; A Giobbie-Hurder; K Gantman; J Savoie; R Scheib; L M Parker; W Y Chen Journal: Cancer Causes Control Date: 2012-02-28 Impact factor: 2.506
Authors: Gillian Libby; Louise A Donnelly; Peter T Donnan; Dario R Alessi; Andrew D Morris; Josie M M Evans Journal: Diabetes Care Date: 2009-06-29 Impact factor: 19.112
Authors: Andrew G Renehan; Marcel Zwahlen; Christoph Minder; Sarah T O'Dwyer; Stephen M Shalet; Matthias Egger Journal: Lancet Date: 2004-04-24 Impact factor: 79.321
Authors: Robert E Schoen; Jeff Schragin; Joel L Weissfeld; F Leland Thaete; Rhobert W Evans; Clifford J Rosen; Lewis H Kuller Journal: Cancer Epidemiol Biomarkers Prev Date: 2002-06 Impact factor: 4.254
Authors: Ahmed Hassoon; Yasmin Baig; Daniel Q Naiman; David D Celentano; Dina Lansey; Vered Stearns; Josef Coresh; Jennifer Schrack; Seth S Martin; Hsin-Chieh Yeh; Hadas Zeilberger; Lawrence J Appel Journal: NPJ Digit Med Date: 2021-12-09
Authors: Jiun-Ruey Hu; Hsin-Chieh Yeh; Noel T Mueller; Lawrence J Appel; Edgar R Miller; Nisa M Maruthur; Gerald J Jerome; Alex R Chang; Allan C Gelber; Stephen P Juraschek Journal: Nutrients Date: 2021-07-31 Impact factor: 5.717
Authors: Curtis Tilves; Hsin-Chieh Yeh; Nisa Maruthur; Stephen P Juraschek; Edgar R Miller; Lawrence J Appel; Noel T Mueller Journal: Int J Obes (Lond) Date: 2022-01-06 Impact factor: 5.551
Authors: Curtis Tilves; Hsin-Chieh Yeh; Nisa Maruthur; Stephen P Juraschek; Edgar Miller; Karen White; Lawrence J Appel; Noel T Mueller Journal: J Am Heart Assoc Date: 2022-06-22 Impact factor: 6.106
Authors: Noel T Mueller; Moira K Differding; Mingyu Zhang; Nisa M Maruthur; Stephen P Juraschek; Edgar R Miller; Lawrence J Appel; Hsin-Chieh Yeh Journal: Diabetes Care Date: 2021-05-18 Impact factor: 19.112